JP2019529570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529570A5 JP2019529570A5 JP2019538565A JP2019538565A JP2019529570A5 JP 2019529570 A5 JP2019529570 A5 JP 2019529570A5 JP 2019538565 A JP2019538565 A JP 2019538565A JP 2019538565 A JP2019538565 A JP 2019538565A JP 2019529570 A5 JP2019529570 A5 JP 2019529570A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- release
- activator
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000012190 activator Substances 0.000 claims 11
- 239000011248 coating agent Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 230000003111 delayed effect Effects 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 claims 6
- 229960001094 midodrine Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 238000013268 sustained release Methods 0.000 claims 5
- 239000012730 sustained-release form Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims 3
- 206010031127 Orthostatic hypotension Diseases 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 206010063080 Postural orthostatic tachycardia syndrome Diseases 0.000 claims 2
- 230000004888 barrier function Effects 0.000 claims 2
- 238000012377 drug delivery Methods 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 208000012219 Autonomic Nervous System disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010038967 Retrograde ejaculation Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 238000007922 dissolution test Methods 0.000 claims 1
- 239000004083 gastrointestinal agent Substances 0.000 claims 1
- 229940127227 gastrointestinal drug Drugs 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 229940100692 oral suspension Drugs 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000007939 sustained release tablet Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402844P | 2016-09-30 | 2016-09-30 | |
| US62/402,844 | 2016-09-30 | ||
| PCT/US2017/054323 WO2018064490A1 (en) | 2016-09-30 | 2017-09-29 | Compositions of midodrine and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529570A JP2019529570A (ja) | 2019-10-17 |
| JP2019529570A5 true JP2019529570A5 (enExample) | 2020-11-12 |
| JP7057365B2 JP7057365B2 (ja) | 2022-04-19 |
Family
ID=61762934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538565A Active JP7057365B2 (ja) | 2016-09-30 | 2017-09-29 | ミドドリンの組成物およびその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US11202760B2 (enExample) |
| EP (1) | EP3518910A4 (enExample) |
| JP (1) | JP7057365B2 (enExample) |
| WO (1) | WO2018064490A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014100733A1 (en) | 2012-12-21 | 2014-06-26 | Mayo Foundation For Medical Education And Research | Methods and materials for treating calcific aortic valve stenosis |
| US11202760B2 (en) | 2016-09-30 | 2021-12-21 | Xenamed Corp. | Compositions of midodrine and methods of using the same |
| US12213953B2 (en) | 2017-12-22 | 2025-02-04 | Xenamed Corp. | Extended release midodrine hydrochloride compositions and methods of use |
| MX2021012409A (es) * | 2019-04-10 | 2021-11-12 | Mayo Found Medical Education & Res | Metodos y materiales para el tratamiento dependiente del genero de la disfuncion cardiovascular. |
| CN110065149B (zh) * | 2019-04-15 | 2021-05-25 | 广西利升石业有限公司 | 生产人造石用的喷涂式脱模剂、制备方法及其使用方法 |
| US20220349008A1 (en) * | 2019-09-09 | 2022-11-03 | The Children's Hospital Of Philadelphia | Novel genetic markers for postural orthostatic tachycardia syndrome (pots) and methods of use thereof for diagnosis and treatment of the same |
| CN112245399B (zh) * | 2020-10-29 | 2023-02-28 | 西南医科大学 | 一种二氢杨梅素胃漂浮丸剂及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3131068A (en) * | 1961-07-24 | 1964-04-28 | American Cyanamid Co | Water-soluble coated edible organic acids |
| DE59003337D1 (de) | 1989-10-16 | 1993-12-09 | Danubia Petrochem Polymere | Pressling mit retardierter Wirkstofffreisetzung. |
| US5360822A (en) | 1990-02-07 | 1994-11-01 | Nippon Shinyaku Co. Ltd. | Sulfonanilide derivatives and medicine |
| US6761904B2 (en) | 2000-03-31 | 2004-07-13 | Nycomed Austria Gmbh | Pharmaceutical kit comprising midodrine as active drug substance |
| EE200200556A (et) | 2000-03-31 | 2004-04-15 | Nycomed Austria Gmbh | Midodriini ja/või desglümidodriini sisaldav kontrollitud vabanemisega farmatseutiline kompositsioon |
| US7070803B2 (en) | 2000-03-31 | 2006-07-04 | Nycomed Austria Gmbh | Controlled release pharmaceutical composition for oral use containing midodrine and/or active metabolite, desglymidodrine |
| US20020147232A1 (en) * | 2000-05-26 | 2002-10-10 | Claus Sundgreen | Pharmaceutical compositions comprising desglymidodrine as an active drug substance |
| US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US9314999B2 (en) | 2008-08-15 | 2016-04-19 | Toray Plastics (America), Inc. | Biaxially oriented polylactic acid film with high barrier |
| EP2480710B1 (en) | 2009-09-25 | 2018-01-24 | Toray Plastics (America) , Inc. | Multi-layer high moisture barrier polylactic acid film and its method of forming |
| FR2953410B1 (fr) | 2009-12-09 | 2012-02-24 | Univ Claude Bernard Lyon | Compositions antivirales pharmaceutiques ou veterinaires |
| WO2012090322A1 (ja) | 2010-12-28 | 2012-07-05 | 積水メディカル株式会社 | 貼付剤 |
| CA2835293C (en) | 2011-06-08 | 2020-08-18 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
| AU2014256944B2 (en) | 2013-04-26 | 2019-06-27 | La Jolla Pharma, Llc | Compositions and methods for treating renal failure |
| EP3142644A1 (en) | 2014-05-16 | 2017-03-22 | Vivus, Inc. | Orally administrable formulations for the controlled release of a pharmacologically active agent |
| US11202760B2 (en) | 2016-09-30 | 2021-12-21 | Xenamed Corp. | Compositions of midodrine and methods of using the same |
| US12213953B2 (en) | 2017-12-22 | 2025-02-04 | Xenamed Corp. | Extended release midodrine hydrochloride compositions and methods of use |
-
2017
- 2017-09-29 US US16/338,317 patent/US11202760B2/en active Active
- 2017-09-29 WO PCT/US2017/054323 patent/WO2018064490A1/en not_active Ceased
- 2017-09-29 JP JP2019538565A patent/JP7057365B2/ja active Active
- 2017-09-29 EP EP17857506.4A patent/EP3518910A4/en active Pending
-
2021
- 2021-11-18 US US17/530,027 patent/US11975103B2/en active Active
-
2024
- 2024-05-06 US US18/656,110 patent/US20250120919A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529570A5 (enExample) | ||
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| JP2011509295A5 (enExample) | ||
| ME02179B (me) | Metoda za lečenje atrijalne fibrilacije | |
| JP2005506367A5 (enExample) | ||
| JP2010505943A (ja) | 時間治療理論に基づく循環器疾患の治療用組合せ製剤 | |
| RU2011110765A (ru) | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения | |
| KR101156054B1 (ko) | 안정한 에페리손 함유 서방성 의약조성물 | |
| JP2018507243A5 (enExample) | ||
| JP2019517542A5 (enExample) | ||
| JP2009215293A5 (enExample) | ||
| FI3710000T3 (fi) | Tradipitantti käytettäväksi gastropareesin hoidossa | |
| JP2005528430A5 (enExample) | ||
| CN107530335A (zh) | 新型药学用途 | |
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| JP2011516544A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2005512946A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| CN113876775B (zh) | 一种青藤碱或其药物可接受的盐作为治疗动脉性肺动脉高压药物的用途 | |
| RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
| JP2019535830A5 (enExample) | ||
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| KR20120089787A (ko) | 염산레르카니디핀 및 발사르탄을 포함하는 복합 제제 및 이의 제조방법 | |
| JP2009522294A5 (enExample) |